Sage Therapeutics Statistics
Total Valuation
SAGE has a market cap or net worth of $9.32 million. The enterprise value is $10.71 million.
| Market Cap | 9.32M |
| Enterprise Value | 10.71M |
Important Dates
The last earnings date was Wednesday, July 30, 2025, after market close.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SAGE has 8.03 billion shares outstanding. The number of shares has decreased by -9.37% in one year.
| Current Share Class | 8.03B |
| Shares Outstanding | 8.03B |
| Shares Change (YoY) | -9.37% |
| Shares Change (QoQ) | +1.85% |
| Owned by Insiders (%) | 9.96% |
| Owned by Institutions (%) | n/a |
| Float | 1.61B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.04 |
| Forward PS | 5.75 |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -55.40 |
| EV / Sales | 18.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.08.
| Current Ratio | 4.82 |
| Quick Ratio | 0.19 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -1.09% and return on invested capital (ROIC) is -0.51%.
| Return on Equity (ROE) | -1.09% |
| Return on Assets (ROA) | -0.49% |
| Return on Invested Capital (ROIC) | -0.51% |
| Return on Capital Employed (ROCE) | -0.82% |
| Revenue Per Employee | $10,191 |
| Profits Per Employee | -$3,391 |
| Employee Count | 353 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0.07 |
Taxes
In the past 12 months, SAGE has paid $15,509 in taxes.
| Income Tax | 15,509 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.63% in the last 52 weeks. The beta is -0.86, so SAGE's price volatility has been lower than the market average.
| Beta (5Y) | -0.86 |
| 52-Week Price Change | -19.63% |
| 50-Day Moving Average | 8.20 |
| 200-Day Moving Average | 7.16 |
| Relative Strength Index (RSI) | 46.61 |
| Average Volume (20 Days) | 3,784,177 |
Short Selling Information
The latest short interest is 2.22 million, so 3.54% of the outstanding shares have been sold short.
| Short Interest | 2.22M |
| Short Previous Month | 2.81M |
| Short % of Shares Out | 3.54% |
| Short % of Float | 3.86% |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SAGE had revenue of $580,903 and -$193,298 in losses. Loss per share was -$0.00.
| Revenue | 580,903 |
| Gross Profit | 292,051 |
| Operating Income | -157,028 |
| Pretax Income | -178,029 |
| Net Income | -193,298 |
| EBITDA | -135,981 |
| EBIT | -157,028 |
| Loss Per Share | -$0.00 |
Balance Sheet
The company has $34,976 in cash and $1.44 million in debt, giving a net cash position of -$1.40 million or -$0.00 per share.
| Cash & Cash Equivalents | 34,976 |
| Total Debt | 1.44M |
| Net Cash | -1.40M |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | 17.58M |
| Book Value Per Share | 0.00 |
| Working Capital | 3.89M |
Cash Flow
| Operating Cash Flow | -118,581 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 50.28%, with operating and profit margins of -27.03% and -33.28%.
| Gross Margin | 50.28% |
| Operating Margin | -27.03% |
| Pretax Margin | -30.65% |
| Profit Margin | -33.28% |
| EBITDA Margin | -23.41% |
| EBIT Margin | -27.03% |
| FCF Margin | n/a |
Dividends & Yields
SAGE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 9.37% |
| Shareholder Yield | 9.37% |
| Earnings Yield | -2.07% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SAGE is $9.37, which is 7.95% higher than the current price. The consensus rating is "Hold".
| Price Target | $9.37 |
| Price Target Difference | 7.95% |
| Analyst Consensus | Hold |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 41.46% |
| EPS Growth Forecast (5Y) | -37.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |